Century Therapeutics (NASDAQ:IPSC) Stock Rating Upgraded by Wall Street Zen

Century Therapeutics (NASDAQ:IPSC) was upgraded by equities researchers at Wall Street Zen from a “sell” rating to a “hold” rating in a research report issued on Sunday.

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Century Therapeutics in a report on Wednesday, October 8th. Four analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $3.75.

Century Therapeutics Stock Performance

Shares of IPSC stock opened at $0.55 on Friday. The firm has a market cap of $47.51 million, a P/E ratio of -1.90 and a beta of 1.78. Century Therapeutics has a fifty-two week low of $0.34 and a fifty-two week high of $1.83. The business’s 50 day moving average price is $0.52 and its 200-day moving average price is $0.54.

Century Therapeutics (NASDAQ:IPSC) last issued its quarterly earnings data on Thursday, August 14th. The company reported ($0.38) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.38). Century Therapeutics had a negative return on equity of 11.53% and a negative net margin of 19.10%. As a group, equities analysts predict that Century Therapeutics will post -1.61 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of IPSC. Prudential Financial Inc. bought a new position in shares of Century Therapeutics during the second quarter valued at $25,000. Qube Research & Technologies Ltd bought a new position in shares of Century Therapeutics during the second quarter valued at $38,000. Y Intercept Hong Kong Ltd bought a new position in shares of Century Therapeutics during the second quarter valued at $50,000. Raymond James Financial Inc. bought a new position in shares of Century Therapeutics during the second quarter valued at $51,000. Finally, AQR Capital Management LLC lifted its holdings in shares of Century Therapeutics by 358.9% during the first quarter. AQR Capital Management LLC now owns 111,079 shares of the company’s stock valued at $53,000 after purchasing an additional 86,875 shares in the last quarter. 50.20% of the stock is owned by institutional investors.

About Century Therapeutics

Century Therapeutics, Inc, a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma.